
Bryan D Hayes PharmD
@pharmertoxguy
EM Pharmacist & Toxicologist @MassGeneralEM | Associate Professor @HarvardMed | Past-President ABAT | EIC PharmERToxGuy.com | @ALiEMteam EM Pharm Pearls
ID: 496399535
https://connects.catalyst.harvard.edu/Profiles/display/Person/157300 18-02-2012 22:41:36
3,3K Tweet
18,18K Takipçi
171 Takip Edilen







Xylazine is in the headlines again with a new DEA alert (dea.gov/alert/dea-repo…). With poisoning, we see effects as we would with other alpha-2 agonists (clonidine, guanfacine) such as hypotension, bradycardia, and lethargy (pubmed.ncbi.nlm.nih.gov/35442125/). cc: David Zimmerman

Xylazine is back in the headlines as an adulterant (dea.gov/alert/dea-repo…). It acts similarly to other alpha-2 agonists (clonidine, guanfacine) and causes hypotension, bradycardia, lethargy, and miosis. Good review on poisonings by David Zimmerman et al. pubmed.ncbi.nlm.nih.gov/35442125/


I spot at least two EM pharmacists on the new Fellow of ASHP (FASHP) induction list. Congrats David Zimmerman and @memusselman! ashp.org/about-ashp/awa…


We love our magnesium in the ED. Here's a new AEM Journal summary on its use as an adjunct in atrial fibrillation: pubmed.ncbi.nlm.nih.gov/37021611/. And, our Academic Life in EM deep-dive from a few years back: aliem.com/magnesium-for-…




>>bit.ly/3LozPQa<< New ACMT Position Statement: End Use of the Term "Excited Delirium" 🧵 Anthony Pizon Louise Kao Ziad Kazzi, MD, FACMT, FAACT, FAAEM, FACEP Andrew Stolbach, MD, MPH @heshiegreshie Kelly Johnson-Arbor Brian Patrick Murray Daniel Ovakim Lewis Nelson Timothy Wiegand, MD, FACMT, FAACT, DFASAM @kavitababu


What a multi-site collaborative effort to see this one through to completion! Free downloads here in Clinical Toxicology: tandfonline.com/eprint/YAZMX2H… Peter Chai Harvard Toxicology




